Olga Trofymenko

National Institutes of Health — United States

Immunology and Microbiology · Life Sciences

9h-index737citations12works6.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HIV Research and Treatment(3), SARS-CoV-2 and COVID-19 Research(3), Malaria Research and Control(2), Influenza Virus Research Studies(2), Virus-based gene therapy research(2)

Publications11 total

Phase 1 trial evaluating safety and pharmacokinetics of HIV-1 broadly neutralizing mAbs 10E8VLS and VRC07-523LS
JCI Insight·2024· 6 citedOpen Access
An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults
Science Translational Medicine·2023· 89 citedOpen Access
Low-dose intravenous and subcutaneous CIS43LS monoclonal antibody for protection against malaria (VRC 612 Part C): a phase 1, adaptive trial
The Lancet Infectious Diseases·2023· 35 citedOpen Access
Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial
The Lancet·2023· 62 citedOpen Access
Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial
EClinicalMedicine·2022· 38 citedOpen Access
Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial
Nature Medicine·2022· 84 citedOpen Access
Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial
Nature Medicine·2022· 153 citedOpen Access
Optimization of the CIS43LS Malarial Monoclonal Antibody and Protection Against Malaria
SSRN Electronic Journal·2022Open Access
Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial
The Lancet Respiratory Medicine·2021· 63 citedOpen Access
Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study
The Lancet·2019· 123 citedOpen Access
The program of mutual interests : a search for new concepts of international education in the context of globalization
School for International Training Digital Collections (School for International Training)·2004

Frequent Co-authors

Ingelise J. Gordon(9), Martin R. Gaudinski(9), Nina M. Berkowitz(8), Emily E. Coates(8), Sandra Vazquez(8), Adrian B. McDermott(8), Jason G. Gall(8), John R. Mascola(8), Julie E. Ledgerwood(8), LaSonji A. Holman(8), Somia P. Hickman(8), Floreliz Mendoza(7), Cynthia S. Hendel(7), Judy Stein(7), Kevin Carlton(7), Larisa Strom(7), Richard A. Koup(7), Pamela Costner(7), Ro Shauna Rothwell(7), Katherine V. Houser(6)